Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2013

View Archived Issues

Biomarker analysis and mental fitness testing for driving aptitude in patients with cirrhosis

Gilead Sciences reviews events of second quarter 2013

Targeting Abeta oligomers for the treatment of Alzheimer's disease

Bayer discloses novel sGC activators for cardiovascular disorders

Baltic Bio synthesizes new AMPK activators for diabetes

Cellmid collaborates on marker for colorectal cancer diagnosis

Preclinical and clinical evaluation of a snake venom polypeptide as an antithrombotic

Ex vivo evaluation of a bispecific antibody for the treatment of patients with hemophilia A

Phase II study of SHACT meets efficacy and safety endpoints

Signature Therapeutics receives award to advance abuse-deterrent oxycodone

Nektar Therapeutics completes enrollment in phase III BEACON study

ReGenX Biosciences and Audentes Therapeutics to develop NAV vector treatments

Summit awarded grant to develop DMD therapy

Spanish researchers discover biomarker for Lewy body dementia diagnosis

Omeros submits NDA to the FDA for OMS-302

IntelligentMDx receives FDA clearance for vancomycin-resistant enterococci assay

BioDelivery Sciences submits NDA to FDA for Bunavail

PrEP trial to evaluate prevention using antiretroviral drugs in HIV-negative individuals

S1 Biopharma initiates phase IIa trial of Lorexys in premenopausal women with HSDD

New company AveXis to focus on new technology for disease treatment

OncoTherapy Science identifies potent drug candidates for a novel kinase target

Cubist Pharmaceuticals signs agreements to acquire two companies

OncoTherapy's phase III trial of peptide cocktail vaccine for pancreatic cancer remains on schedule

MolecularMD obtains license for cancer diagnosis technology

Takeda receives marketing authorization in China for Nesina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...